Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced that it will present new data on its drug FILSPARI® (sparsentan) at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy (IgAN). The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。